Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration

Ophthalmology

Volumn 114, Issue 9, 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PEGAPTANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; URINALYSIS; VISUAL ACUITY; VISUAL DISORDER; VITAL SIGN; VITREOUS FLOATERS;

EID: 34548262708     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.02.021     Document Type: Article

References (36)

1. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
2. Gass J.D. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63 suppl (1967) 1-139
3. Green W.R., and Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100 (1993) 1519-1535
4. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114 (1996) 964-970
5. Tolentino M.J., McLeod D.S., Taomoto M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002) 373-385
6. Amano S., Rohan R., Kuroki M., et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39 (1998) 18-22
7. Adamis A.P., Shima D.T., Tolentino M.J., et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114 (1996) 66-71
8. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
9. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92 (1995) 10457-10461
10. Krzystolik M.G., Afshari M.A., Adamis A.P., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120 (2002) 338-346
11. Ishida S., Usui T., Yamashiro K., et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198 (2003) 483-489
12. Matsuoka M., Ogata N., Otsuji T., et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 88 (2004) 809-815
13. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
14. Otani A., Takagi H., Oh H., et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40 (1999) 1912-1920
15. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
16. White R.R., Sullenger B.A., and Rusconi C.P. Developing aptamers into therapeutics. J Clin Invest 106 (2000) 929-934
17. Wlotzka B., Leva S., Eschgfaller B., et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A 99 (2002) 8898-8902
18. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55 (2003) 1261-1277
19. Walsh W., Shah A., and Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 47 (2003) 554-558
20. Sun X., Yang Z., Li S., et al. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res 63 (2003) 8377-8383
21. Drolet D.W., Nelson J., Tucker C.E., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17 (2000) 1503-1510
22. Siddiqui M.A.A., and Keating G.M. Pegaptanib in exudative age-related macular degeneration. Drugs 65 (2005) 1571-1577
23. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration. Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113 (2006) 992-1001
24. Northrop Grumman. MedDRA. Available at: http://www.meddramsso.com/MSSOWeb/index.htm. Accessed February 19, 2007.
25. Sosenko J.M., Hu D., Welty T., et al. Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study. Diabetes Care 25 (2002) 1078-1084
26. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 (2006) 2130-2139. http://content.onlinejacc.org/cgi/reprint/47/10/2130 Available at: http://content.onlinejacc.org/cgi/reprint/47/10/2130. Accessed June 6, 2006.
27. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 suppl (2005) 25-33
28. Nguyen Q.D., Shah S.M., Hafiz G., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522-1532
29. Larsson A., Sköldenberg E., and Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5 (2002) 107-110
30. Luttun A., and Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?. J Clin Invest 111 (2003) 600-602
31. Liu M.H., Jin H., Floten H.S., et al. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg 73 (2002) 819-824
32. Wei W., Jin H., Chen Z.W., et al. Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 44 (2004) 615-621
33. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 (2003) 707-716
34. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
35. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
36. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431